Navigation Links
Monogram Announces Conference Call
Date:10/23/2008

LEADING HIV PHYSICIAN, Dr. DAVID HARDY, TO DISCUSS CLINICAL USE OF THE TROFILE(TM) ASSAY AND SELZENTRY(TM) IN CONJUNCTION WITH THE THIRD QUARTER

2008 FINANCIAL RESULTS CONFERENCE CALL

SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) announced that it will hold a conference call on Monday, October 27, 2008 at 4:30 p.m. (Eastern Time) to discuss the clinical use of Monogram's Trofile(TM) Assay in conjunction with Pfizer's CCR5 antagonist, Selzentry(TM). Monogram will also review its third quarter 2008 financial results. The call will be hosted by William D. Young, Chairman & CEO of Monogram. Dr. David Hardy will participate in the call. Dr. Hardy is Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and is Associate Professor of Medicine-in-Residence at the David Geffen School of Medicine at UCLA.

To participate in the live teleconference, please call (877) 604-9672, or (719) 325-4896 for international callers, fifteen minutes before the conference begins. Live audio of the call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Access to live and archived audio of the conference call will be available on the Investor Relations section at http://www.monogrambio.com. Following the live broadcast, a replay of the call will also be available at (888) 203-1112 or (719) 457-0820 for international callers, through Sunday, November 9, 2008. The replay passcode is 4461917. The information provided on the teleconference is only accurate at the time of the conference call, and Monogram will take no r
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Monogram Receives NASDAQ Notification
2. Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
4. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
5. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
6. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
7. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
8. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
9. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
10. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
11. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... University of Leicester has furthered our understanding of ... create new materials using nanosized ,building blocks,. , ... prestigious academic journal Physical Review Letters , ... rich detail the structure and internal atomic motion ... and a single helium atom. , The technique ...
(Date:7/25/2014)... WABC Radio show out of New York ... Young will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, ... in pets. Dr. Harman first visited the show in ... for pets suffering from osteoarthritis and other degenerative diseases, as ... forward. , Young has invited Dr. Harman back to dial ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/25/2014)... Sinovac Biotech Ltd. (Nasdaq: SVA ), ... , today announced that it will release its unaudited ... after market close on Thursday, August 14, 2014 EDT. The ... opening on Friday, August 15, 2014, at 8:00 a.m. EDT ... to review the Company,s financial results and provide an update ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... , EAST BRUNSWICK, N.J., Sept. 8 Savient ... abstracts relating to KRYSTEXXA(TM) (pegloticase) development and treatment failure gout will ... in Philadelphia from October 16-21, 2009. The posters will be ... and include: , , , ...
... , CAMBRIDGE, Massachusetts, September 8 ... the global specialty biopharmaceutical company, is,committed to doing everything ... imiglucerase supply shortage. Shire is pleased to be,able to ... previously,anticipated commercial launch world wide. , ...
... , SAN DIEGO, Sept. 8 Biomatrica, Inc., the ... key appointments that will expand the breadth of leadership and commercial ... continued rapid growth in the development and commercialization of products for ... , Martin Latterich, Ph.D., has joined the company ...
Cached Biology Technology:Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 2Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 3Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 4Update on velaglucerase alfa 2Update on velaglucerase alfa 3Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 2Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 3Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 4Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 5
(Date:7/25/2014)... the Terra satellite show the different areas that have been ... The burn scars show up as reddish-brown splotches of ... across the remote parts of Eastern Russia in the Sakha ... instrument, it is still possible to see the smoke ... noted below show the devastating number of fires that have ...
(Date:7/25/2014)... of biomedical engineering at the University of Houston, ... and artificial organ development., "Introduction to Tissue Engineering: ... entering into the field of artificial organ development. ... engineering at UH, served as a series editor ... are other published books on the subject of ...
(Date:7/25/2014)... (DTT), which is derived from diffusion tensor imaging ... tracts, such as the corticospinal tract, the rubrospinal ... corticospinal tract is known to be a major ... brain. Several studies have reported on injury of ... some studies have demonstrated recovery of a corticospinal ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2
... pressure were recently identified in a comprehensive international ... study, in which Uppsala University researchers participated, are ... Nature Genetics . High blood pressure ... Previous studies have shown that it is extremely ...
... May 8 Military and civilian personnel from the ... local homeland security, law enforcement and other first-responder personnel ... been encouraged to register and attend the 2009 Force ... held at Stafford Regional Airport and Marine Corps Base, ...
... and south sides of a house may decrease summertime ... a recent study* of California homes by researchers from ... the U.S. Department of Agriculture (USDA). The first ... the effects of shade on 460 single-family homes in ...
Cached Biology News:Comprehensive genetic study paves way for new blood-pressure medicines 2Demonstration Features Commercial Technology for Combating Terrorism 2New study: Home energy savings are made in the shade 2
Moue Serum 8-12 Weeks Old...
... is collected off the clot fasted non-Swiss Albino mice ... Available Anticoagulants: N-02: Citrate N-04: ... Potassium Oxalate N-10: EDTA (Na) ... CPD N-09: K3EDTA N-11: ...
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
Biology Products: